Nightingale Research is one of Australia’s largest private clinical research organisations. With collectively over 35 years of clinical trials experience, we are at the cutting edge of cardiovascular research.
Nightingale Research is one of Australia’s largest private clinical research organisations. With collectively over 35 years of clinical trials experience, we are at the cutting edge of cardiovascular research.
Our clinical trials coordinators are the most experienced in Australia.
Clinical trials offer patients the opportunity to participate in new therapies with so potentially improving the health of the community.
For more information please contact us.
Dulaglutide vs Tirzepatide – GLP1 inhibitors in diabetes with high cardiovascular risk – NOW RECRUITING – please contact Hazel Morrison. (Hazel@nightingalecardiology.com)
Contact us to registerUpdated 28/01/21
Repatha vs placebo – PCSK9 inhibition in high risk cardiovascular patients with high cholesterols – started – Nov 2019 – currently recruiting (Hazel@nightingalecardiology.com)
Contact us to registerUpdated 28/01/21
Bempadoic acid vs placebo in high risk of cardiovascular disease and statin intolerant patients – recruitment completed.
Sotagliflozin vs placebo in diabetes and reduced renal function – recruitment completed.
Omecamtiv mecarbil vs placebo in reduced ejection fraction heart failure – recruitment completed.
Empagliflozin vs placebo for preserved ejection fraction heart failure – recruitment completed.
© Nightingale Cardiology 2020
Health Link: nighting